EMA recommends 4SC's resminostat for orphan designation
This article was originally published in Scrip
Executive Summary
The European Medicines Agency (EMA) has adopted a positive opinion for 4SC's resminostat to be given orphan drug designation for the treatment of hepatocellular carcinoma, which was a second piece of recent good news for the company, as they were able to present positive data for the drug in June (scripintelligence.com, scripintelligence.com, 23 June 2011). 4SC now has lots riding on resminostat's success, as its share price plunged by a third last month when its lead candidate, vidofludimus, failed to meet its primary endpoint (scripintelligence.com scripintelligence.com, 8 June 2011).